AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$SMMT

Soni Manmeet Singh purchased $722K of SMMT

Soni Manmeet Singh (COO and CFO) purchased 50,000 shares of Summit Therapeutics Inc. (SMMT) at an average of $14.44 ($14.43–$14.46, $0.72M total) across 2 trades on 2026-06-04.

Original reporting
SEC EDGAR · Soni Manmeet Singh
Published Jun 4, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SMMTBullishMed
01

Why it matters

The transaction adds to insider ownership, potentially influencing investor perception and short‑term price action.

02

Market read

First‑report insider purchase may prompt modest buying interest in SMMT.

03

What to watch

The purchase size relative to market cap is modest; market may already price in insider confidence.

Relevance 6/10Novelty 5/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

COO/CFO Soni Manmeet Singh bought 50,000 shares for $722,250, increasing his stake to over 3.1 million shares.

Expected impact

likely upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is sizable for a micro‑cap and comes from a senior executive, which traders often view as a bullish signal.

Market effects

Sector

May signal confidence in Summit Therapeutics' pipeline, modestly supporting biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Low global relevance; impact confined to the stock and its immediate peers.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • company
    Summit Therapeutics Inc.

    Biopharmaceutical company developing therapies for rare diseases.

  • person
    Soni Manmeet Singh

    Chief Operating Officer and Chief Financial Officer of Summit Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SMMT insider trading history →

Related articles

OCT 21
$SMMTMedAI 8/10

Summit Therapeutics (SMMT) Partners with ECOG-ACRIN for Phase II

Summit Therapeutics (SMMT) partners with ECOG-ACRIN to start a Phase II/III trial for ivonescimab in advanced biliary tract cancer. The study will compare ivonescimab plus chemotherapy against standard immunotherapy regimens. Summit's P/S ratio is 560.0x, reflecting high growth expectations. Insider buying totals $114.6M over the past year. The company's GF Score is 29, indicating challenges in profitability and growth.

gurufocus.com3 min
OCT 21
$SMMTMed

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Summit Therapeutics (SMMT) and ECOG-ACRIN will collaborate on a Phase II/III trial of ivonescimab for biliary tract cancer, starting in Q4 2026. The study will compare ivonescimab with chemotherapy against pembrolizumab or durvalumab plus chemotherapy. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, with prior positive Phase III results in China. Summit aims to expand ivonescimab's development in areas of high unmet need.

finanznachrichten.de2 min